---
title: "Linzess (linaclotide) in irritable bowel syndrome with constipation: Specific populations questions"
description: "Specific populations questions on Linzess (linaclotide) in irritable bowel syndrome with constipation, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Pediatric use. Questions: At what age can children take Linzess for IBS-C? Was Linzess studied in adults 65 and older with IBS-C? 2 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/linzess--irritable-bowel-syndrome-with-constipation/specific-populations"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Linzess (linaclotide) in irritable bowel syndrome with constipation: Specific populations questions

Manufacturer: AbbVie, Inc.; Ironwood Pharmaceuticals, Inc.  
Prescribing information: [Linzess](https://www.rxabbvie.com/pdf/linzess_pi.pdf)

Specific populations questions that apply to every indication of Linzess are on [Linzess (linaclotide), all indications: Specific populations](https://www.evicenter.com/medical-information/linzess/specific-populations).

## Pediatric use

<a id="linzess-pediatric-age"></a>

### At what age can children take Linzess for IBS-C?

Applies to: Irritable bowel syndrome with constipation (IBS-C) in pediatric patients 7 years of age and older

> “The safety and effectiveness of LINZESS for the treatment of IBS-C have been established in 
> pediatric patients 7 years of age and older. Use of LINZESS for this indication is supported by 
> evidence from adequate and well-controlled studies in adults and pediatric patients 7 to 17 
> years of age. The safety of LINZESS in adult and pediatric patients in these clinical studies 
> was similar [see Adverse Reactions (6.1) and Clinical Studies (14.2)]. 
>
> The safety and effectiveness of LINZESS for the treatment of IBS-C have not been established 
> in pediatric patients less than 7 years of age.”

Source: [LINZESS: Prescribing information, page 10, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=10)

> “LINZESS is contraindicated in: 
> • Patients less than 2 years of age due to the risk of serious dehydration [see Warnings 
> and Precautions (5.1), Use in Specific Populations (8.4)].”

Source: [LINZESS: Prescribing information, page 4, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=4)

## Specific populations

<a id="linzess-older-adults"></a>

### Was Linzess studied in adults 65 and older with IBS-C?

Applies to: Irritable bowel syndrome with constipation (IBS-C) in adults

> “Of 2219 IBS-C patients in the placebo-controlled clinical studies of LINZESS (Trials 1, 2, and 
> 6), 154 (7%) were 65 years of age and over, while 34 (2%) were 75 years and over. Clinical 
> studies of LINZESS did not include sufficient numbers of patients aged 65 years and over to 
> determine whether they respond differently from younger patients.”

Source: [LINZESS: Prescribing information, page 11, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=11)

## Related pages
- [Medical information: Linzess (linaclotide): Irritable bowel syndrome with constipation](https://www.evicenter.com/medical-information/linzess--irritable-bowel-syndrome-with-constipation)
- [Clinical trials](https://www.evicenter.com/medical-information/linzess--irritable-bowel-syndrome-with-constipation/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/linzess--irritable-bowel-syndrome-with-constipation/safety)
- [Dosing and administration](https://www.evicenter.com/medical-information/linzess--irritable-bowel-syndrome-with-constipation/dosing-and-administration)
- [Guidelines](https://www.evicenter.com/medical-information/linzess--irritable-bowel-syndrome-with-constipation/guidelines)
